Organization

UCB Pharma, Colombes, France

3 abstracts

Abstract
BIMEKIZUMAB EFFICACY THROUGH 3 YEARS IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS: LONG-TERM POOLED ANALYSIS FROM BE BRIGHT
Org: UCB Pharma, Morrisville, North Carolina, United States of America, UCB Pharma, Monheim, Germany, UCB Pharma, Colombes, France,
Abstract
BIMEKIZUMAB MAINTAINED EFFICACY RESPONSES THROUGH 52 WEEKS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM TWO PHASE 3 STUDIES
Org: Royal National Hospital of Rheumatic Diseases, Bath, United Kingdom, Centre for Therapeutic Innovation, University of Bath, Department of Life Sciences, Bath, United Kingdom, University of Occupational and Environmental Health, The First Department of Internal Medicine, Kitakyushu, Fukuoka, Japan, Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, UCB Pharma, Slough, United Kingdom,